Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Eur J Immunol. 2011 Feb 11;41(3):863–872. doi: 10.1002/eji.201040649

Figure 4. IFNα treatment elicits short-lived ASCs in NZB/W mice.

Figure 4

(A) Absence of long-lived plasma cells. NZB/W mice were treated at day 0 with CT or IFNα Adv and then continuously fed BrdU for 35 days starting at day 21 post-treatment. Mice were sacrificed at indicated times, and BrdU staining of B220lowCD138+ cells was analyzed by FACS. Results are means ± SD of 3 to 5 mice per experimental group from two independent experiments (B) NZB/W mice were untreated (UNT) or treated with IFNα Adv and either with PBS (IFNα) or with 20 mg/kg cyclophosphamide (IFNα/CYC) on 3 consecutive days starting on day 21 after initiation of IFNα treatment. Mice were sacrificed 4 days after the last injection of cyclophosphamide, and spleen anti-ssDNA (left) or anti-dsDNA(right) ASCs were measured by ELISPOT. Each symbol represents an individual mouse. Data shown are representative of three independent experiments.